MIRM Earnings Date: Nov 3, 2026 (Estimated) — Mirum Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is MIRM's next earnings date?
Mirum Pharmaceuticals, Inc. (MIRM) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.49 on revenue of $178.1M.
How did MIRM do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Mirum Pharmaceuticals, Inc. posted EPS of -$0.80 versus the -$0.74 estimate, a miss of 0.0%. Revenue was $176.2M against a $166.3M estimate. The stock's 1-day post-earnings move was -11.0%.
How much does MIRM stock move after earnings?
MIRM beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.1% (up or down) in the day after earnings.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.74 | -0.80 | +0.00% | $176.2M | ❌ Miss | -11.04% | -6.45% | -4.88% |
| 2026-05-06 | Q1 2026 | -0.36 | -0.50 | -38.89% | $159.9M | ❌ Miss | -6.50% | -0.84% | -15.08% |
| 2026-02-25 | Q4 2025 | 0.04 | -0.12 | -400.00% | $148.9M | ❌ Miss | -15.13% | -14.34% | -18.17% |
| 2025-11-04 | Q3 2025 | -0.14 | 0.05 | +135.71% | $133.0M | ✅ Beat | -1.24% | +0.49% | +0.79% |
| 2025-08-06 | Q2 2025 | -0.32 | -0.12 | +62.50% | $127.8M | ✅ Beat | +12.04% | +22.01% | +42.54% |
| 2025-02-26 | Q4 2024 | -0.25 | -0.49 | -96.00% | $99.4M | ❌ Miss | -7.02% | -11.64% | -8.79% |
| 2024-11-12 | Q3 2024 | -0.45 | -0.30 | +33.33% | $90.4M | ✅ Beat | +1.61% | -0.46% | +4.81% |
| 2024-08-07 | Q2 2024 | -0.47 | -0.52 | -10.64% | $77.9M | ❌ Miss | +2.34% | +6.49% | +5.54% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $176.2M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 78.5% | $138.3M | +44.8% | $79.1M | $86.9M | $95.5M | $103.7M |
| Non-US | 21.5% | $37.9M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.